□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □□□□□□□□□□□□□□□□□□□□□□□□□ □ □□ □ □□□□□ □ □□ □ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □ □ □ □ □ □ □ □ □□□□□□□□□□□ □ □ □□□□□□□□□ □□ □□□□ □□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□Gust Professor 招へい教授 片桐 豊雅 Toyomasa KATAGIRI 072-641-9811 Fax 072-641-98121）がん抑制因子を利用したがん創薬研究2）がん特異的分子の機能解析を通じた創薬開発研究3.）家族性乳がん新規原因遺伝子の同定4）難治性がんにおけるオミックス解析基盤の構築および薬剤耐性の分子機構解明とその制御に関する研究開発 (JST がんムーンショットプロジェクト）t-katagiri@nibiohn.go.jp招へい教授 片桐 豊雅1. Harada A*, Kunii M*, Kurokawa K*, Sumi T*, Kanda S, Zhang Y, Nadanaka S, Hirosawa KM, Tokunaga K, Tojima T, Taniguchi M, Moriwaki K, Yoshimura S, Yamamoto Hino M, Goto S, Katagiri T, Kume S, Hayashi-Nishino M, Nakano M, Miyoshi E, Suzuki KGN, Kitagawa H, Nakano A. Dynamic movement of the Golgi unit and its glycosylation enzyme zones. Nat Communi, 2024 May 27;15(1):45142. Namkaew J, Zhang J, Yamakawa N, Hamada Y, Tsugawa K, Oyadomari M, Miyake M, Katagiri T, Oyadomari S. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Lett. 2023 Nov 28;582:216509. 3. Sudo H, Tsuji BA, Sugyo, A Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T. Head-to-head comparison of three bifunctional chelating agents reveals DOTAGA promising for 225Ac labeling of the anti-FZD10 antibody OTSA101. Cancer Sci. 2023 Dec;114(12):4677-4690.4. Saito A*, Kamikawa Y, Ito T, Matsuhisa K, Asada Kitamura R, Kaneko M, Okamoto T, Yoshimaru T, Matsushita Y, Katagiri T, and Imaizumi K. p53-independent tumor suppression by cell cycle arrest via CREB/ATF transcription factor OASIS. Cell Rep. 2023 May 30;42(5):112479.5. Okuda K, Nakahara K, Ito A, Iijima Y, Nomura R, Kumar A, Fujikawa K, Adachi K, Shimada Y, Fujio S, Yamamoto R, Takasugi N, Onuma K, Osaki M, Okada F, Ukegawa T, Takeuchi Y, Yasui N, Yamashita A, Marusawa H, Matsushita Y, Katagiri T, Shibata T, Uchida K, Niu SY, Lang NB, Nakamura T, Zhang KYJ, Lipton SA, Uehara T.. Pivotal role 1 for S-nitrosylation of DNA methyltransferase in epigenetic regulation. Nat Communi. 2023 Feb 4;14(1):621.6. Yoshimaru T, Nakamura Y, Katagiri T*. Functional Genomics for Breast Cancer Drug Target Discovery. J Hum Genet. 2021 Sep;66(9):927-935. 7. Yoshimaru T, Ono M, Bando Y, Chen YA, Mizuguchi K, Shima H, Komatsu M, Imoto I, Izumi K, Honda J, Miyoshi Y, Sasa M, *Katagiri T. A-kinase anchoring protein BIG3 coordinates oestrogen signaling in breast cancer cells. Nat Commun. 2017 May 30;8:154278. Yoshimaru T, Komatsu M, Matsuo T, Chen YA, Murakami Y, Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T*. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 2013;4:2443.□□□□□□□□ □□□□□□□□□□□□Laboratory of Biofunctional Molecular Medicine, National Institute of Biomedical Innovation, National Institutes of Biomedical Innovation, Health and Nutrition
元のページ ../index.html#49